Current Approaches to Management of Newly Diagnosed Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35234302/
Major developments in the treatment of multiple myeloma over the past decade have led to a continued improvement in survival. Significant progress has been made with deeper and longer remissions...
Conclusion/Relevance: Among transplant ineligible patients, those with standard risk MM should receive DRd continued until disease progression, while bortezomib containing regimens (VRd or VRd lite) can be considered for high-risk patients. Finally, standard risk patients should receive lenalidomide maintenance after induction/ASCT, while a...
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment - Cell Death & Disease
Source : https://www.nature.com/articles/s41419-022-04651-w
Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome...
Conclusion: Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.
SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35201323/
Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress quickly with this therapy, highlighting the need for...
Relevance: These results highlight the preclinical efficacy of SAR442085 and support the current evaluation of this next-generation anti-CD38 antibody in phase I clinical development in patients with relapsed/refractory MM.
Targeted Drug Delivery for the Treatment of Blood Cancers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35209102/
Blood cancers are a type of liquid tumor which means cancer is present in the body fluid. Multiple myeloma, leukemia, and lymphoma are the three common types of blood cancers....
Conclusion: In this review, we describe the current targeting strategies for blood cancers and recently investigated and approved drug delivery system formulations for blood cancers. In addition, we also discuss current challenges in the application of drug delivery systems for treating blood cancers.
Towards a unified approach for multiple myeloma care in Kenya - proceedings of the Inaugural Multiple Myeloma Congress - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35178147/
The rising burden of multiple myeloma in Kenya has not been met by a commensurate effort for control. Patients and practitioners struggle with unavailability and unaffordability of diagnostics, drugs and...
Conclusion/Relevance: The underlying principle of recommendations developed during the congress was collaboration among in-country and international practitioners, researchers and policy experts from private and public sector. This partnership of stakeholders bears the potential of pooling scarce resources and for collective advocacy towards...